mProX™ Human TNFRSF17 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

TNFRSF17, also known as B cell maturation antigen (BCMA), is a target for immunotherapies in multiple myeloma (MM). However, antigen escape from BCMA-targeted therapies can occur, leading to resistance. This study investigated the mechanisms of antigen escape in MM patients treated with BCMA or GPRC5D-targeted immunotherapies. The researchers performed whole-genome sequencing and copy number variation analysis on patient samples and identified various mechanisms of antigen escape, including BCMA-negative clones with TNFRSF17 deletions and BCMA mutations that rendered anti-BCMA therapies ineffective. They also found cases of GPRC5D mutations after anti-GPRC5D therapy. The study highlights the importance of considering the tumor antigen landscape for optimal design and selection of targeted immunotherapies in MM. Another study focused on oral squamous cell carcinoma (OSCC) and used bioinformatics analysis to identify potential molecular mechanisms and prognostic markers. The researchers analyzed gene expression datasets and identified differentially expressed genes (DEGs) associated with OSCC. They found that TNFRSF17, along with other genes, was a hub gene and a favorable prognostic marker for OSCC. The study suggests that TNFRSF17 could be used as a potential therapeutic target and tumor marker in OSCC. Additionally, a study investigated the influences of COVID-19 co-infection with influenza virus on chronic obstructive pulmonary disease (COPD). The researchers used bioinformatics and systems biology approaches to identify DEGs associated with COVID-19, influenza virus A, and COPD. TNFRSF17 was among the top hub genes identified, suggesting its potential role in the co-infection. The study also identified several drugs that could potentially treat the co-infection. Lastly, a study examined the serum levels and significance of soluble BCMA in childhood-onset systemic lupus erythematosus (cSLE) with renal involvement. The researchers found that serum BCMA levels were significantly increased in cSLE patients compared to healthy controls. They also observed a positive correlation between serum BCMA levels and disease activity in cSLE patients. The study suggests that serum BCMA could serve as a biomarker in cSLE patients. Overall, these studies highlight the diverse applications of TNFRSF17 in different diseases and provide insights into its role in immunotherapies, prognostic markers, and disease mechanisms.